Analysis

Ptc Therapeutics, Inc. (PTCT) Stock Analysis

Ptc Therapeutics, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysis connected to PTCT.

websitePTCT/analysis/PTCT

Ptc Therapeutics, Inc.

Ptc Therapeutics, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysisconnected to PTCT.

Stock profile

Ticker

PTCT

Asset type

Stock

Market cap

$6.55B

Sector

Health Technology

Industry

Pharmaceuticals: Major

Currency

USD

Ticker listings

Ptc Therapeutics, Inc. may appear across multiple exchanges or ticker formats. 6ix consolidates those listings around the canonical analysis page for discovery.

  • PTCT primary listing
  • BH3
  • A1W0MW
  • P91

Latest Ptc Therapeutics, Inc. news

PTC Therapeutics Announces Pricing of Convertible Notes Offering to Refinance 2026 Convertible Notes

PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced the pricing of $500.0 million aggregate principal amount of 0% Convertible Senior Notes due 2031 (the "Notes") in a privat...

PTC Therapeutics Announces Proposed Convertible Notes Offering to Refinance 2026 Convertible Notes

PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced that it intends to offer, subject to market conditions and other factors, $500.0 million aggregate principal amount of Con...

PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results

PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the first quarter ended March 31, 2026.

Ardena Strengthens Executive Team to Drive its Next Phase of Growth

Ardena appoints CFO and CCO Ardena welcomes Ben Ash as Chief Financial Officer and Henny Zijlstra as Chief Commercial Officer, strengthening the company’s leadership team as it ...

PTC Therapeutics Reports Positive Topline Results from Month 24 Interim Analysis of PIVOT-HD Extension Study of Votoplam

PTC Therapeutics, Inc. (NASDAQ: PTCT) today reported positive topline results from the 24-month interim analysis of the PIVOT-HD long-term extension study, with favorable dose-d...

Research sections

Valuation

Review valuation context for Ptc Therapeutics, Inc..

Future growth

Review future growth context for Ptc Therapeutics, Inc..

Past performance

Review past performance context for Ptc Therapeutics, Inc..

Financial health

Review financial health context for Ptc Therapeutics, Inc..

Dividend

Review dividend context for Ptc Therapeutics, Inc..

Management

Review management context for Ptc Therapeutics, Inc..

Ownership

Review ownership context for Ptc Therapeutics, Inc..

Other information

Review other information context for Ptc Therapeutics, Inc..

Community

Review community context for Ptc Therapeutics, Inc..